PTGX vs UTHR
Protagonist Therapeutics, Inc. vs United Therapeutics — AI-powered side-by-side comparison
PTGX
Protagonist Therapeutics, Inc.
65
Buy
VS
UTHR
United Therapeutics
72
Buy
| Metric | PTGX | UTHR |
|---|
| AI Score |
65
|
72
|
| Price |
$148.25
|
$514.89
|
| P/E Ratio |
121.74×
|
17.05×
|
| ROE |
-21.2%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.9%
|
86.1%
|
| Debt / Equity |
0.01×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
68.1
|
52.2
|
| Beta |
1.794
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for PTGX versus UTHR.
UTHR leads by 7 points.
UTHR scores 72/100 (Buy) versus PTGX at 65/100 (Buy).
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.